首页 > 最新文献

Personalized medicine最新文献

英文 中文
CYP1A1 common gene polymorphisms and ischemic stroke risk: a meta-analysis and a structural examination. CYP1A1常见基因多态性与缺血性卒中风险:荟萃分析和结构检查。
IF 2.3 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2023-05-01 DOI: 10.2217/pme-2022-0113
Mohammad Karimian, Faezeh Karimnia

Aim: CYP1A1 is a metabolizing enzyme and key polymorphisms in its gene may contribute to the risk of ischemic stroke. This study aimed to investigate the association of the rs4646903 and rs1048943 polymorphisms of CYP1A1 with stroke risk in a meta-analysis and a bioinformatic approach. Materials & methods: An electronic search was conducted and, after the screening procedure, six eligible studies were included in the meta-analysis. Some bioinformatic tools were employed to analyze the effects of rs4646903 and rs1048943 on CYP1A1 gene function. Results: There was a significant association between rs4646903 and the reduced risk of ischemic stroke, whereas there was no significant association for rs1048943. In silico analysis showed that rs4646903 and rs1048943 polymorphisms could affect the gene expression and cofactor affinity, respectively. Conclusion: Based on these results, rs4646903 may be a protective genetic factor against ischemic stroke.

目的:CYP1A1是一种代谢酶,其基因的关键多态性可能与缺血性卒中的风险有关。本研究旨在通过荟萃分析和生物信息学方法探讨CYP1A1基因rs4646903和rs1048943多态性与卒中风险的关系。材料与方法:进行电子检索,经过筛选程序,6项符合条件的研究被纳入meta分析。利用生物信息学工具分析rs4646903和rs1048943对CYP1A1基因功能的影响。结果:rs4646903与缺血性卒中风险降低有显著相关性,而rs1048943与缺血性卒中风险降低无显著相关性。结果表明,rs4646903多态性和rs1048943多态性分别影响基因表达和辅因子亲和力。结论:rs4646903可能是缺血性脑卒中的保护性遗传因子。
{"title":"CYP1A1 common gene polymorphisms and ischemic stroke risk: a meta-analysis and a structural examination.","authors":"Mohammad Karimian,&nbsp;Faezeh Karimnia","doi":"10.2217/pme-2022-0113","DOIUrl":"https://doi.org/10.2217/pme-2022-0113","url":null,"abstract":"<p><p><b>Aim:</b> CYP1A1 is a metabolizing enzyme and key polymorphisms in its gene may contribute to the risk of ischemic stroke. This study aimed to investigate the association of the rs4646903 and rs1048943 polymorphisms of <i>CYP1A1</i> with stroke risk in a meta-analysis and a bioinformatic approach. <b>Materials & methods:</b> An electronic search was conducted and, after the screening procedure, six eligible studies were included in the meta-analysis. Some bioinformatic tools were employed to analyze the effects of rs4646903 and rs1048943 on <i>CYP1A1</i> gene function. <b>Results:</b> There was a significant association between rs4646903 and the reduced risk of ischemic stroke, whereas there was no significant association for rs1048943. <i>In silico</i> analysis showed that rs4646903 and rs1048943 polymorphisms could affect the gene expression and cofactor affinity, respectively. <b>Conclusion:</b> Based on these results, rs4646903 may be a protective genetic factor against ischemic stroke.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"20 3","pages":"271-281"},"PeriodicalIF":2.3,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10321564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preliminary radiogenomic study of hepatitis B virus-related hepatocellular carcinoma: associations between MRI features and mutations. 乙型肝炎病毒相关肝细胞癌的初步放射基因组学研究:MRI特征与突变之间的关系
IF 2.3 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2023-05-01 DOI: 10.2217/pme-2022-0093
Shanshan Gao, Feihang Wang, Wei Sun, Xianling Qian, Yuan Ji, Yunfeng Cheng, Xiaolin Wang, Lingxiao Liu, Ruofan Sheng, Mengsu Zeng

Aim: To investigate associations between MRI features and high-frequency mutations of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Methods: This study included 58 HCC patients who underwent contrast-enhanced MRI prior to surgical resection and genome sequencing. MRI features and mutation information were evaluated. Results: The top five most frequently mutated genes in HCC were TP53 (53.45%), TAF1 (24.14%), PDE4DIP (22.41%), ABCA13 (18.97%) and LRP1B (17.24%). Mutations in TP53 and LRP1B were associated with tumor necrosis (p = 0.035) and mosaic architecture (p = 0.015), respectively. Mutations in ABCA13 were associated with mosaic architecture (p = 0.025) and necrosis (p = 0.010). Conclusion: This preliminary radiogenomics analysis showed associations between MRI features and high-frequency mutations in HBV-related HCCs.

目的:探讨乙型肝炎病毒(HBV)相关肝细胞癌(HCC)的MRI特征与高频突变之间的关系。方法:本研究纳入了58例HCC患者,他们在手术切除前进行了对比增强MRI检查并进行了基因组测序。评估MRI特征和突变信息。结果:HCC中前5位突变基因分别为TP53(53.45%)、TAF1(24.14%)、PDE4DIP(22.41%)、ABCA13(18.97%)和LRP1B(17.24%)。TP53和LRP1B突变分别与肿瘤坏死(p = 0.035)和镶嵌结构(p = 0.015)相关。ABCA13突变与马赛克结构(p = 0.025)和坏死(p = 0.010)相关。结论:这项初步的放射基因组学分析显示,MRI特征与hbv相关hcc的高频突变之间存在关联。
{"title":"Preliminary radiogenomic study of hepatitis B virus-related hepatocellular carcinoma: associations between MRI features and mutations.","authors":"Shanshan Gao,&nbsp;Feihang Wang,&nbsp;Wei Sun,&nbsp;Xianling Qian,&nbsp;Yuan Ji,&nbsp;Yunfeng Cheng,&nbsp;Xiaolin Wang,&nbsp;Lingxiao Liu,&nbsp;Ruofan Sheng,&nbsp;Mengsu Zeng","doi":"10.2217/pme-2022-0093","DOIUrl":"https://doi.org/10.2217/pme-2022-0093","url":null,"abstract":"<p><p><b>Aim:</b> To investigate associations between MRI features and high-frequency mutations of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). <b>Methods:</b> This study included 58 HCC patients who underwent contrast-enhanced MRI prior to surgical resection and genome sequencing. MRI features and mutation information were evaluated. <b>Results:</b> The top five most frequently mutated genes in HCC were <i>TP53</i> (53.45%), <i>TAF1</i> (24.14%), <i>PDE4DIP</i> (22.41%), <i>ABCA13</i> (18.97%) and <i>LRP1B</i> (17.24%). Mutations in <i>TP53</i> and <i>LRP1B</i> were associated with tumor necrosis (p = 0.035) and mosaic architecture (p = 0.015), respectively. Mutations in <i>ABCA13</i> were associated with mosaic architecture (p = 0.025) and necrosis (p = 0.010). <b>Conclusion:</b> This preliminary radiogenomics analysis showed associations between MRI features and high-frequency mutations in HBV-related HCCs.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"20 3","pages":"215-225"},"PeriodicalIF":2.3,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10305680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Research and innovation in personalized medicine: a descriptive synthesis of actors in the EU and China. 个性化医疗的研究与创新:欧盟和中国参与者的描述性综合。
IF 2.3 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2023-05-01 DOI: 10.2217/pme-2023-0003
Francesco Andrea Causio, Ilda Hoxhaj, Flavia Beccia, Marzia Di Marcantonio, Timo Strohäker, Chiara Cadeddu, Walter Ricciardi, Stefania Boccia

Aim: Research and innovation (R&I) actors are fundamental in shortening the translational gap of personalized medicine in health systems. In the context of the 'Integrating China in the International Consortium for Personalized Medicine' project, we aimed to map the current landscape of R&I actors in the field of personalized medicine in the EU and China. Methods: A two-phase desk research study was conducted. Results: We identified 78 R&I actors. Research and technology organizations were the most frequent in both the EU and China. The identified R&I actors were active in a wide range of fields. The EU and China have many different R&I actors addressing personalized medicine-related issues, with few characteristics in common. Conclusion: More efforts are needed to ensure these R&I actors are encouraged to work together to bridge each other's gaps.

目的:研究与创新行为体是缩短卫生系统个性化医疗转化差距的基础。在“将中国融入国际个性化医疗联盟”项目的背景下,我们旨在绘制出欧盟和中国个性化医疗领域R&I参与者的现状。方法:采用两期台式研究方法。结果:共鉴定出78名R&I演员。研究和技术组织在欧盟和中国都是最常见的。已确定的R&I参与者活跃在广泛的领域。欧盟和中国在解决个性化医疗相关问题上有许多不同的研发参与者,几乎没有共同点。结论:需要做出更多努力,以确保鼓励这些R&I参与者共同努力,弥合彼此的差距。
{"title":"Research and innovation in personalized medicine: a descriptive synthesis of actors in the EU and China.","authors":"Francesco Andrea Causio,&nbsp;Ilda Hoxhaj,&nbsp;Flavia Beccia,&nbsp;Marzia Di Marcantonio,&nbsp;Timo Strohäker,&nbsp;Chiara Cadeddu,&nbsp;Walter Ricciardi,&nbsp;Stefania Boccia","doi":"10.2217/pme-2023-0003","DOIUrl":"https://doi.org/10.2217/pme-2023-0003","url":null,"abstract":"<p><p><b>Aim:</b> Research and innovation (R&I) actors are fundamental in shortening the translational gap of personalized medicine in health systems. In the context of the 'Integrating China in the International Consortium for Personalized Medicine' project, we aimed to map the current landscape of R&I actors in the field of personalized medicine in the EU and China. <b>Methods:</b> A two-phase desk research study was conducted. <b>Results:</b> We identified 78 R&I actors. Research and technology organizations were the most frequent in both the EU and China. The identified R&I actors were active in a wide range of fields. The EU and China have many different R&I actors addressing personalized medicine-related issues, with few characteristics in common. <b>Conclusion:</b> More efforts are needed to ensure these R&I actors are encouraged to work together to bridge each other's gaps.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"20 3","pages":"227-238"},"PeriodicalIF":2.3,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10321563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nanosensor technologies and the digital transformation of healthcare. 纳米传感器技术和医疗保健的数字化转型。
IF 2.3 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2023-05-01 DOI: 10.2217/pme-2022-0065
Emem E Udoh, Melody Hermel, Murtaza I Bharmal, Aditi Nayak, Siddharth Patel, Mark Butlin, Sanjeev P Bhavnani

Nanosensors are nanoscale devices that measure physical attributes and convert these signals into analyzable information. In preparation, for the impending reality of nanosensors in clinical practice, we confront important questions regarding the evidence supporting widespread device use. Our objectives are to demonstrate the value and implications for new nanosensors as they relate to the next phase of remote patient monitoring and to apply lessons learned from digital health devices through real-world examples.

纳米传感器是测量物理属性并将这些信号转换为可分析信息的纳米级设备。在准备工作中,纳米传感器在临床实践中迫在眉睫的现实,我们面临着关于支持广泛使用设备的证据的重要问题。我们的目标是展示新型纳米传感器的价值和影响,因为它们与下一阶段的远程患者监测有关,并通过现实世界的例子应用从数字医疗设备中吸取的经验教训。
{"title":"Nanosensor technologies and the digital transformation of healthcare.","authors":"Emem E Udoh,&nbsp;Melody Hermel,&nbsp;Murtaza I Bharmal,&nbsp;Aditi Nayak,&nbsp;Siddharth Patel,&nbsp;Mark Butlin,&nbsp;Sanjeev P Bhavnani","doi":"10.2217/pme-2022-0065","DOIUrl":"https://doi.org/10.2217/pme-2022-0065","url":null,"abstract":"<p><p>Nanosensors are nanoscale devices that measure physical attributes and convert these signals into analyzable information. In preparation, for the impending reality of nanosensors in clinical practice, we confront important questions regarding the evidence supporting widespread device use. Our objectives are to demonstrate the value and implications for new nanosensors as they relate to the next phase of remote patient monitoring and to apply lessons learned from digital health devices through real-world examples.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"20 3","pages":"251-269"},"PeriodicalIF":2.3,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9950438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pathology-supported genetic testing presents opportunities for improved disability outcomes in multiple sclerosis. 病理支持的基因检测为改善多发性硬化症的残疾结果提供了机会。
IF 2.3 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2023-03-01 DOI: 10.2217/pme-2022-0016
Clint Johannes, Kelebogile E Moremi, Merlisa C Kemp, Lindiwe Whati, Penelope Engel-Hills, Martin Kidd, Ronald van Toorn, Mariaan Jaftha, Susan J van Rensburg, Maritha J Kotze

Background: Lipid metabolism may impact disability in people with multiple sclerosis (pwMS). Methods: Fifty-one pwMS entered an ultrasound and MRI study, of whom 19 had followed a pathology-supported genetic testing program for more than 10 years (pwMS-ON). Genetic variation, blood biochemistry, vascular blood flow velocities, diet and exercise were investigated. Results: pwMS-ON had significantly lower (p < 0.01) disability (Expanded Disability Status Scale) than pwMS not on the program (1.91 ± 0.75 vs 3.87 ± 2.32). A genetic variant in the lipid transporter FABP2 gene (rs1799883; 2445G>A, A54T) was significantly associated (p < 0.01) with disability in pwMS not on the program, but not in pwMS-ON (p = 0.88). Vascular blood flow velocities were lower in the presence of the A-allele. Conclusion: Pathology-supported genetic testing may provide guidance for lifestyle interventions with a significant impact on improved disability in pwMS.

背景:脂质代谢可能影响多发性硬化症(pwMS)患者的残疾。方法:51例pwMS进入超声和MRI研究,其中19例遵循病理支持的基因检测计划超过10年(pwMS- on)。研究了遗传变异、血液生化、血管血流速度、饮食和运动。结果:pwMS-ON的FABP2基因(rs1799883;2445G>A, A54T)显著相关(p结论:病理支持的基因检测可能为生活方式干预提供指导,对改善pwMS的残疾有显著影响。
{"title":"Pathology-supported genetic testing presents opportunities for improved disability outcomes in multiple sclerosis.","authors":"Clint Johannes,&nbsp;Kelebogile E Moremi,&nbsp;Merlisa C Kemp,&nbsp;Lindiwe Whati,&nbsp;Penelope Engel-Hills,&nbsp;Martin Kidd,&nbsp;Ronald van Toorn,&nbsp;Mariaan Jaftha,&nbsp;Susan J van Rensburg,&nbsp;Maritha J Kotze","doi":"10.2217/pme-2022-0016","DOIUrl":"https://doi.org/10.2217/pme-2022-0016","url":null,"abstract":"<p><p><b>Background:</b> Lipid metabolism may impact disability in people with multiple sclerosis (pwMS). <b>Methods:</b> Fifty-one pwMS entered an ultrasound and MRI study, of whom 19 had followed a pathology-supported genetic testing program for more than 10 years (pwMS-ON). Genetic variation, blood biochemistry, vascular blood flow velocities, diet and exercise were investigated. <b>Results:</b> pwMS-ON had significantly lower (p < 0.01) disability (Expanded Disability Status Scale) than pwMS not on the program (1.91 ± 0.75 vs 3.87 ± 2.32). A genetic variant in the lipid transporter <i>FABP2</i> gene (rs1799883; 2445G>A, A54T) was significantly associated (p < 0.01) with disability in pwMS not on the program, but not in pwMS-ON (p = 0.88). Vascular blood flow velocities were lower in the presence of the A-allele. <b>Conclusion:</b> Pathology-supported genetic testing may provide guidance for lifestyle interventions with a significant impact on improved disability in pwMS.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"20 2","pages":"107-130"},"PeriodicalIF":2.3,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10010366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Genetic predisposition for the development of lamotrigine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis: a systematic review and meta-analysis. 拉莫三嗪诱导的Stevens-Johnson综合征/中毒性表皮坏死松解的遗传易感因素:一项系统回顾和荟萃分析。
IF 2.3 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2023-03-01 DOI: 10.2217/pme-2022-0126
Sayan Kumar Das, Ananyan Sampath, Sameer Uz Zaman, Ayan Kumar Pati, Shubham Atal

Studies report an association between the expression of HLA alleles and lamotrigine (LTG)-induced Stevens-Johnson syndrome (SJS). This systematic review and meta-analysis evaluates the association between HLA alleles and LTG-induced SJS in different populations. Two alleles, HLA-B*0702 and HLA-C*0702, were deemed to be protective; five alleles, HLA-B*1502, HLA-B*4403, HLA-A*2402, CYP2C19*2 and HLA-B*38, may play a role in LTG-induced SJS, for which only data studying HLA-B*1502 could be extracted. The pooled odds ratio of 2.88, 95% CI of 1.60-5.17 and p-value of 0.0004 establish the presence of HLA-B*1502 as a major risk factor for the development of LTG-induced SJS/toxic epidermal necrolysis (TEN). Although multiple alleles that may play a role in the development of LTG-induced SJS/TEN were identified, the expression of the risk alleles may be ancestry-specific, and genetic screening is warranted for preventing this life-threatening adverse drug reaction.

研究报告了HLA等位基因的表达与拉莫三嗪(LTG)诱导的史蒂文斯-约翰逊综合征(SJS)之间的关联。本系统综述和荟萃分析评估了HLA等位基因与不同人群中ltg诱导的SJS之间的关系。HLA-B*0702和HLA-C*0702两个等位基因被认为具有保护作用;HLA-B*1502、HLA-B*4403、HLA-A*2402、CYP2C19*2和HLA-B*38这5个等位基因可能在ltg诱导的SJS中发挥作用,目前只能提取HLA-B*1502的相关数据。合并优势比为2.88,95% CI为1.60-5.17,p值为0.0004,确定HLA-B*1502是ltg诱导的SJS/中毒性表皮坏死松解(TEN)发生的主要危险因素。虽然已经确定了多个可能在ltg诱导的SJS/TEN发展中起作用的等位基因,但风险等位基因的表达可能是遗传特异性的,为了预防这种危及生命的药物不良反应,有必要进行遗传筛查。
{"title":"Genetic predisposition for the development of lamotrigine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis: a systematic review and meta-analysis.","authors":"Sayan Kumar Das,&nbsp;Ananyan Sampath,&nbsp;Sameer Uz Zaman,&nbsp;Ayan Kumar Pati,&nbsp;Shubham Atal","doi":"10.2217/pme-2022-0126","DOIUrl":"https://doi.org/10.2217/pme-2022-0126","url":null,"abstract":"<p><p>Studies report an association between the expression of <i>HLA</i> alleles and lamotrigine (LTG)-induced Stevens-Johnson syndrome (SJS). This systematic review and meta-analysis evaluates the association between <i>HLA</i> alleles and LTG-induced SJS in different populations. Two alleles, <i>HLA-B*0702</i> and <i>HLA-C*0702</i>, were deemed to be protective; five alleles, <i>HLA-B*1502</i>, <i>HLA-B*4403</i>, <i>HLA-A*2402</i>, <i>CYP2C19*2</i> and <i>HLA-B*38</i>, may play a role in LTG-induced SJS, for which only data studying <i>HLA-B*1502</i> could be extracted. The pooled odds ratio of 2.88, 95% CI of 1.60-5.17 and p-value of 0.0004 establish the presence of <i>HLA-B*1502</i> as a major risk factor for the development of LTG-induced SJS/toxic epidermal necrolysis (TEN). Although multiple alleles that may play a role in the development of LTG-induced SJS/TEN were identified, the expression of the risk alleles may be ancestry-specific, and genetic screening is warranted for preventing this life-threatening adverse drug reaction.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"20 2","pages":"201-213"},"PeriodicalIF":2.3,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10321562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biomarker testing in patients diagnosed with advanced/metastatic medullary thyroid cancer in the USA. 美国晚期/转移性甲状腺髓样癌患者的生物标志物检测
IF 2.3 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2023-03-01 DOI: 10.2217/pme-2022-0050
Naleen Raj Bhandari, Lisa M Hess, Rohan C Parikh, Anthony N Sireci, Peter M Krein, James A Kaye

Aim: To describe real-world testing patterns for RET in US patients with advanced/metastatic medullary thyroid cancer and determine consistency of real-world testing practices with national guidelines. Materials & methods: The authors performed a retrospective medical record analysis of patients with advanced/metastatic medullary thyroid cancer who initiated systemic therapy between 2013 and 2018. Seventy-five US-based oncologists collected the data using a customized electronic data collection form. Results: A total of 59.6% (121 of 203) of patients underwent testing for RET, and 37.2% (45 of 121) had a RET mutation, of which 55.6% were identified as RET mutation-positive before initial diagnosis. Overall, 90 (44.3%) patients were tested for biomarkers on or after initial diagnosis, with RET being the most tested (95.6%) biomarker. Conclusion: The authors' findings suggest an opportunity to improve testing rates in accordance with treatment guidelines.

目的:描述美国晚期/转移性甲状腺髓样癌患者RET的实际检测模式,并确定实际检测实践与国家指南的一致性。材料和方法:作者对2013年至2018年间开始全身治疗的晚期/转移性甲状腺髓样癌患者进行了回顾性医疗记录分析。75名美国肿瘤学家使用定制的电子数据收集表格收集数据。结果:203例患者中有121例(59.6%)接受了RET检测,其中有45例(37.2%)存在RET突变,其中55.6%的患者在初诊前RET突变阳性。总体而言,90例(44.3%)患者在初次诊断时或之后进行了生物标志物检测,RET是检测最多的(95.6%)生物标志物。结论:作者的发现提示了根据治疗指南提高检测率的机会。
{"title":"Biomarker testing in patients diagnosed with advanced/metastatic medullary thyroid cancer in the USA.","authors":"Naleen Raj Bhandari,&nbsp;Lisa M Hess,&nbsp;Rohan C Parikh,&nbsp;Anthony N Sireci,&nbsp;Peter M Krein,&nbsp;James A Kaye","doi":"10.2217/pme-2022-0050","DOIUrl":"https://doi.org/10.2217/pme-2022-0050","url":null,"abstract":"<p><p><b>Aim:</b> To describe real-world testing patterns for <i>RET</i> in US patients with advanced/metastatic medullary thyroid cancer and determine consistency of real-world testing practices with national guidelines. <b>Materials & methods:</b> The authors performed a retrospective medical record analysis of patients with advanced/metastatic medullary thyroid cancer who initiated systemic therapy between 2013 and 2018. Seventy-five US-based oncologists collected the data using a customized electronic data collection form. <b>Results:</b> A total of 59.6% (121 of 203) of patients underwent testing for <i>RET</i>, and 37.2% (45 of 121) had a <i>RET</i> mutation, of which 55.6% were identified as <i>RET</i> mutation-positive before initial diagnosis. Overall, 90 (44.3%) patients were tested for biomarkers on or after initial diagnosis, with <i>RET</i> being the most tested (95.6%) biomarker. <b>Conclusion:</b> The authors' findings suggest an opportunity to improve testing rates in accordance with treatment guidelines.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"20 2","pages":"131-142"},"PeriodicalIF":2.3,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9940105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A visfatin gene promoter polymorphism (rs1319501) is associated with susceptibility to nonalcoholic fatty liver disease. 内脏脂肪素基因启动子多态性(rs1319501)与非酒精性脂肪肝的易感性相关。
IF 2.3 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2023-03-01 DOI: 10.2217/pme-2022-0100
Touraj Mahmoudi, Donya Ghorbani, Gholamreza Rezamand, Niloufar Dehestan, Golnaz Jeddi, Asadollah Asadi, Hossein Nobakht, Reza Dabiri, Hamid Farahani, Seidamir Pasha Tabaeian, Mohammad Reza Zali

Background: Considering the role of visfatin in nonalcoholic fatty liver disease (NAFLD), a growing global epidemic, this article explores the potential association between the visfatin gene (NAMPT) and NAFLD. Methods: We used the PCR-restriction fragment length polymorphism method to genotype the rs1319501 promoter variant of the NAMPT gene in 154 patients with biopsy-proven NAFLD and 158 controls in this case-control genetic association study. Results: The 'CC+TC' genotype of NAMPT rs1319501 in comparison to the 'TT' genotype occurred less frequently in the cases with NAFLD than the controls, and the difference remained significant after adjustment for confounding factors (p = 0.029; odds ratio = 0.55; 95% CI = 0.31-0.82). Conclusion: This study showed, for the first time, that the carriers of the NAMPT rs1319501 'CC+TC' genotype had a 45% decreased risk for NAFLD.

背景:考虑到visfatin在非酒精性脂肪性肝病(NAFLD)中的作用,本文探讨了visfatin基因(NAMPT)与NAFLD之间的潜在联系。方法:在本病例-对照遗传关联研究中,我们采用pcr -限制性片段长度多态性方法对154例活检证实的NAFLD患者和158例对照患者的NAMPT基因rs1319501启动子变异进行基因分型。结果:NAMPT rs1319501“CC+TC”基因型在NAFLD患者中的发生率低于“TT”基因型,校正混杂因素后差异仍有统计学意义(p = 0.029;优势比= 0.55;95% ci = 0.31-0.82)。结论:本研究首次表明,携带NAMPT rs1319501“CC+TC”基因型的NAFLD风险降低45%。
{"title":"A visfatin gene promoter polymorphism (rs1319501) is associated with susceptibility to nonalcoholic fatty liver disease.","authors":"Touraj Mahmoudi,&nbsp;Donya Ghorbani,&nbsp;Gholamreza Rezamand,&nbsp;Niloufar Dehestan,&nbsp;Golnaz Jeddi,&nbsp;Asadollah Asadi,&nbsp;Hossein Nobakht,&nbsp;Reza Dabiri,&nbsp;Hamid Farahani,&nbsp;Seidamir Pasha Tabaeian,&nbsp;Mohammad Reza Zali","doi":"10.2217/pme-2022-0100","DOIUrl":"https://doi.org/10.2217/pme-2022-0100","url":null,"abstract":"<p><p><b>Background:</b> Considering the role of visfatin in nonalcoholic fatty liver disease (NAFLD), a growing global epidemic, this article explores the potential association between the visfatin gene (<i>NAMPT</i>) and NAFLD. <b>Methods:</b> We used the PCR-restriction fragment length polymorphism method to genotype the rs1319501 promoter variant of the <i>NAMPT</i> gene in 154 patients with biopsy-proven NAFLD and 158 controls in this case-control genetic association study. <b>Results:</b> The 'CC+TC' genotype of <i>NAMPT</i> rs1319501 in comparison to the 'TT' genotype occurred less frequently in the cases with NAFLD than the controls, and the difference remained significant after adjustment for confounding factors (p = 0.029; odds ratio = 0.55; 95% CI = 0.31-0.82). <b>Conclusion:</b> This study showed, for the first time, that the carriers of the <i>NAMPT</i> rs1319501 'CC+TC' genotype had a 45% decreased risk for NAFLD.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"20 2","pages":"157-165"},"PeriodicalIF":2.3,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10003194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Application of transcriptomics and proteomics in pulmonary arterial hypertension. 转录组学和蛋白质组学在肺动脉高压中的应用。
IF 2.3 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2023-03-01 DOI: 10.2217/pme-2023-0020
Jinrui Jiang, Siyun Liu, Huijuan Yang, Yingjie Lv, Ping Ma, Qingbin Xu, Ru Zhou

The onset and progression of pulmonary arterial hypertension (PAH), a malignant disease, are associated with environmental and epigenetic factors. Recent advancements in transcriptomics and proteomics technology have provided new insights into PAH and identified novel gene targets involved in the development of the disease. Transcriptomic analysis has led to the discovery of possible novel pathways, such as miR-483 targeting several PAH-related genes and a mechanistic link between the increase in HERV-K mRNA and protein. Proteomic analysis has revealed crucial details, including the loss of SIRT3 activity and the significance of the CLIC4/Arf6 pathway in PAH pathogenesis. Gene profiles and protein interaction networks of PAH have been analyzed, clarifying the roles of differentially expressed genes or proteins in the occurrence and development of PAH. This article discusses these recent advances.

肺动脉高压(PAH)是一种恶性疾病,其发病和发展与环境和表观遗传因素有关。转录组学和蛋白质组学技术的最新进展为多环芳烃提供了新的见解,并确定了参与该疾病发展的新基因靶点。转录组学分析已经发现了可能的新途径,例如miR-483靶向几种pah相关基因,以及HERV-K mRNA和蛋白增加之间的机制联系。蛋白质组学分析揭示了关键的细节,包括SIRT3活性的丧失和CLIC4/Arf6通路在PAH发病机制中的意义。通过对多环芳烃基因谱和蛋白相互作用网络的分析,阐明了差异表达基因或蛋白在多环芳烃发生发展中的作用。本文将讨论这些最新进展。
{"title":"Application of transcriptomics and proteomics in pulmonary arterial hypertension.","authors":"Jinrui Jiang,&nbsp;Siyun Liu,&nbsp;Huijuan Yang,&nbsp;Yingjie Lv,&nbsp;Ping Ma,&nbsp;Qingbin Xu,&nbsp;Ru Zhou","doi":"10.2217/pme-2023-0020","DOIUrl":"https://doi.org/10.2217/pme-2023-0020","url":null,"abstract":"<p><p>The onset and progression of pulmonary arterial hypertension (PAH), a malignant disease, are associated with environmental and epigenetic factors. Recent advancements in transcriptomics and proteomics technology have provided new insights into PAH and identified novel gene targets involved in the development of the disease. Transcriptomic analysis has led to the discovery of possible novel pathways, such as miR-483 targeting several PAH-related genes and a mechanistic link between the increase in <i>HERV-K</i> mRNA and protein. Proteomic analysis has revealed crucial details, including the loss of SIRT3 activity and the significance of the CLIC4/Arf6 pathway in PAH pathogenesis. Gene profiles and protein interaction networks of PAH have been analyzed, clarifying the roles of differentially expressed genes or proteins in the occurrence and development of PAH. This article discusses these recent advances.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"20 2","pages":"183-192"},"PeriodicalIF":2.3,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10305676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Correlation between plasma lncRNA CASC11 and malignancy in lung adenocarcinoma patients and the prognostic value of lncRNA CASC11. 肺腺癌患者血浆lncRNA CASC11与恶性肿瘤的相关性及lncRNA CASC11的预后价值
IF 2.3 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2023-03-01 DOI: 10.2217/pme-2022-0104
Xiaojuan Gu, Yanlin Zhang, Hao Xiong

Objective: To study the connection between lncRNA CASC11 plasma expression and clinical characteristics as well as prognoses of patients. Methods: Sixty lung adenocarcinoma (LUAD) patients and 60 healthy adults participated in this research. LncRNA CASC11 expression was detected by quantitative real-time PCR and the relationships between lncRNA CASC11 plasma expression and patient prognosis and clinical characteristics were analyzed. Results: LncRNA CASC11 was highly expressed in LUAD tissues and plasma (p < 0.05). Receiver operating characteristic curve analysis indicated the diagnostic value of lncRNA CASC11 in LUAD (p < 0.0001). Higher plasma lncRNA CASC11 expression indicated worse patient prognoses (p < 0.05). Plasma lncRNA CASC11 level was also closely related to tumor differentiation and tumor-node-metastasis stage (p < 0.05). Conclusion: Plasma lncRNA CASC11 may be a potential biomarker for LUAD diagnosis and prognosis.

目的:探讨lncRNA cas11血浆表达与患者临床特征及预后的关系。方法:60例肺腺癌(LUAD)患者和60例健康成人参与本研究。采用实时荧光定量PCR检测LncRNA CASC11表达,分析LncRNA CASC11血浆表达与患者预后及临床特征的关系。结果:LncRNA CASC11在LUAD组织和血浆中高表达(p CASC11在LUAD中表达),表明患者预后较差(p CASC11水平与肿瘤分化和肿瘤淋巴结转移分期密切相关(p结论:血浆LncRNA CASC11可能是LUAD诊断和预后的潜在生物标志物。
{"title":"Correlation between plasma lncRNA <i>CASC11</i> and malignancy in lung adenocarcinoma patients and the prognostic value of lncRNA <i>CASC11</i>.","authors":"Xiaojuan Gu,&nbsp;Yanlin Zhang,&nbsp;Hao Xiong","doi":"10.2217/pme-2022-0104","DOIUrl":"https://doi.org/10.2217/pme-2022-0104","url":null,"abstract":"<p><p><b>Objective:</b> To study the connection between lncRNA <i>CASC11</i> plasma expression and clinical characteristics as well as prognoses of patients. <b>Methods:</b> Sixty lung adenocarcinoma (LUAD) patients and 60 healthy adults participated in this research. LncRNA <i>CASC11</i> expression was detected by quantitative real-time PCR and the relationships between lncRNA <i>CASC11</i> plasma expression and patient prognosis and clinical characteristics were analyzed. <b>Results:</b> LncRNA <i>CASC11</i> was highly expressed in LUAD tissues and plasma (p < 0.05). Receiver operating characteristic curve analysis indicated the diagnostic value of lncRNA <i>CASC11</i> in LUAD (p < 0.0001). Higher plasma lncRNA <i>CASC11</i> expression indicated worse patient prognoses (p < 0.05). Plasma lncRNA <i>CASC11</i> level was also closely related to tumor differentiation and tumor-node-metastasis stage (p < 0.05). <b>Conclusion:</b> Plasma lncRNA <i>CASC11</i> may be a potential biomarker for LUAD diagnosis and prognosis.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"20 2","pages":"167-173"},"PeriodicalIF":2.3,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10321058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Personalized medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1